ReviewLiver international : official journal of the International Association for the Study of the Liver2021
Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: A cost-of-illness analysis.
Review in Liver international : official journal of the International Association for the Study of the Liver, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 4 syntheses or guidelines pooled it, 133 citations in OpenAlex.
- Clinical Outcomes and Non-Invasive Testing in Metabolic Dysfunction-Associated Steatohepatitis With Cirrhosis: A Systematic Review.Liver international : official journal of the International Association for the Study of the Liver · 2026Pooled it
- Epidemiology of Metabolic Dysfunction-Associated Steatotic Liver Disease in South Asian Ethnicities: A Systematic Review and Meta-Analysis.Journal of gastroenterology and hepatology · 2025Pooled it
- Uncovering the NAFLD burden in people living with HIV from high- and middle-income nations: a meta-analysis with a data gap from Subsaharan Africa.Journal of the International AIDS Society · 2023Pooled it
- The Economic Burden of Non-Alcoholic Steatohepatitis: A Systematic Review.PharmacoEconomics · 2022Pooled it
- Clinical Trial: Phase 3 Trial of Resmetirom Versus Placebo in Metabolic Dysfunction-Associated Steatohepatitis-Reanalysis of Fibrosis Stage 2-3 Subset.Alimentary pharmacology & therapeutics · 2026Trial
- Epidemiological and socio-economic burden of MASH (previously known as NASH) in Europe: a systematic literature review.Journal of endocrinological investigation · 2026Review
- Multispectral Photoacoustic Imaging Detects Altered Hepatic Hemodynamics and Lipid in Early STZ-Induced Type 1 Diabetic Liver Injury.Journal of biophotonics · 2026Article
- Understanding the economic and healthcare burden of metabolic dysfunction-associated steatohepatitis: a real-world claims data analysis from Germany.Journal of comparative effectiveness research · 2026Article
- Differential Impact of Metabolic Bariatric Surgery Versus Semaglutide on Adverse Hepatic and Extrahepatic Outcomes in Individuals With Metabolic Dysfunction-Associated Steatotic Liver Disease and Type 2 Diabetes.Diabetes, obesity & metabolism · 2026Article
- Assessing Europe's policy readiness to confront the MASLD/MASH public health threat.The Lancet regional health. Europe · 2026Review
- From MASLD to MELD 3.0: Integrating the Spectrum of Liver Disease Risk Stratification into Primary Care.The Eurasian journal of medicine · 2026Article
- Overcoming Patient Access Barriers in Complex Conditions: Lessons from Schizophrenia for Broader Healthcare Applications.Journal of market access & health policy · 2026Article
- Association of cholesterol, high-density lipoprotein and glucose (CHG) index with mortality risk in metabolic dysfunction-associated steatotic liver disease (MASLD) adults: results from two prospective cohorts.Cardiovascular diabetology · 2026Article
- "Efficacy of SGLT2 inhibitors in non-diabetic non-alcoholic fatty liver disease: a systematic review and meta-analysis".Journal of diabetes and metabolic disorders · 2025Article
- Real-world work productivity is impaired in people with metabolic dysfunction-associated steatotic liver disease in the USA.JHEP reports : innovation in hepatology · 2025Article
- Incidence of major cardiovascular events in patients with metabolic dysfunction-associated steatotic liver disease in the general population.European journal of heart failure · 2025Article
- Proteomic signatures reflect effects of semaglutide treatment for MASH.JHEP reports : innovation in hepatology · 2025Article
- Metabolic Dysfunction-Associated Steatohepatitis Diagnosis and Management in Germany: Insights From an Expert Consensus Panel.Liver international : official journal of the International Association for the Study of the Liver · 2025Article
- A call for doubling the diagnostic rate of at-risk metabolic dysfunction-associated steatohepatitis.The Lancet regional health. Europe · 2025Review
- The weight of choices: Prioritizing lifestyle over GLP-1 receptor agonist therapy in managing MASLD.JHEP reports : innovation in hepatology · 2025Article
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors at 20 institutions in 7 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsNon-alcoholic steatohepatitis (NASH) is a chronic disease that can progress to end-stage liver disease (ESLD). A large proportion of early-stage NASH patients remain undiagnosed compared to those with advanced fibrosis, who are more likely to receive disease management interventions. This study estimated the disease burden and economic impact of diagnosed NASH in the adult population of France, Germany, Italy, Spain and the United Kingdom in 2018.
methodsThe socioeconomic burden of diagnosed NASH was estimated using cost-of-illness methodology applying a prevalence approach to estimate the number of adults with NASH and the attributable economic and wellbeing costs. Given undiagnosed patients do not incur costs in the study, the probability of diagnosis is central to cost estimation. The analysis was based on a literature review, databases and consultation with clinical experts, economists and patient groups.
resultsThe proportion of adult NASH patients with a diagnosis ranged from 11.9% to 12.7% across countries, which increased to 38.8%-39.1% for advanced fibrosis (F3-F4 compensated cirrhosis). Total economic costs were €8548-19 546M. Of these, health system costs were €619-1292M. Total wellbeing costs were €41 536-90 379M. The majority of the undiagnosed population (87.3%-88.2% of total prevalence) was found to have early-stage NASH, which, left untreated, may progress to more resource consuming ESLD over time.
conclusionsThis study found that the majority of economic and wellbeing costs of NASH are experienced in late disease stages. Earlier diagnosis and care of NASH patients could reduce future healthcare costs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.